A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf
.
Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches
2017
Lancet Neurology
Progressive supranuclear palsy (PSP), previously believed to be a common cause of atypical parkinsonism, is now recognised as a range of motor and behavioural syndromes that are associated with a characteristic 4-repeat tau neuropathology. New research criteria that recognise early presentations of PSP and operationalise diagnosis of the full spectrum of clinical phenotypes have been reported. The Movement Disorders Society PSP diagnostic criteria include syndromes with few or mild symptoms
doi:10.1016/s1474-4422(17)30157-6
pmid:28653647
pmcid:PMC5802400
fatcat:gyto7vjo5raevl5rmqddqbmm2e